To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules
Study Details
Study Description
Brief Summary
-
Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in both fed and fasted states
-
Evaluate the safety and tolerability of the test compound administered orally
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Safety parameters assessed included medical history, physical examination, vital signs, 12-lead ECGs, clinical laboratory testing and adverse event assessment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HC-ER 20 mg capsule (fasted) Single oral dose of a HC-ER 20 mg capsule (fasted) |
Drug: HC-ER 20 mg capsule (fasted)
Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
Other Names:
|
| Experimental: HC-ER 20 mg capsule (fed) Single oral dose of HC-ER 20mg capsule (fed) |
Drug: HC-ER 20 mg capsule (fed)
Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in both fed and fast states [Day 1-2]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy Volunteers.
-
Aged greater than 18 and less than 45 years.
-
Were medically healthy with no clinically significant abnormality on the basis of medical history, physical examination and laboratory evaluations
-
Volunteer consented to participate in the study.
-
Female volunteers were included if they were surgically sterile, or using an acceptable method of birth control defined as either oral, injectable, implantable, or barrier methods of contraception (ie, diaphragm with spermicidal cream, intrauterine device (IUD) with spermicidal cream or condom with spermicidal cream).
Exclusion Criteria:
-
Participants were in a clinical trial within the previous 90 days or participants in a narcotic analgesic study within the previous 12 months.
-
Deviation in excess of 10% from the ideal body weight for height according to the Metropolitan Life Insurance Tables (1983 edition).
-
History of drug or alcohol abuse at any time in the past
-
History of hypersensitivity to the study drug or similar compounds or to acetaminophen.
-
Therapeutic use (for any reason) of narcotic analgesics within the previous year.
-
Subjects who used tricyclic antidepressants or monoamine oxidase inhibitors at any time in the past.
-
Subjects with a history of, or clinical signs suggestive of, chronic obstructive airways disease.
-
Receipt of any prescription medication (except birth control) within 2 weeks prior to entry into the study or receipt of non-prescription or over-the-counter medication within one week of study commencement. (Vitamin supplements were acceptable).
-
Blood donation within the 90 days previous to study entry.
-
Female volunteers with a positive serum pregnancy test, or at risk of becoming pregnant during the study.
-
Volunteers with a history of smoking (must not have smoked within the last 6 months).
-
Volunteers with any clinical/biochemical impairment of liver function, or receipt of known hepatic enzyme inducing or inhibiting agents within 30 days prior to entry into the study.
-
History or presence of significant hepatic, renal, endocrine, cardiac, nervous, gastrointestinal, pulmonary or metabolic disorders.
-
Any condition or history that the investigator considered might increase the risk to the volunteer or interfere with the evaluation of data.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Zogenix, Inc.
Investigators
- Principal Investigator: A. Johnston Stewart, MB, MRCGP, Zogenix, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ELN-0302002